AVROBIO is committed to developing gene therapies that have the potential to transform the treatment of rare diseases. To accomplish this, we collaborate with many researchers, individuals living with genetic disorders, patient groups and physicians and we work closely with regulatory agencies.
Clinical trials serve a vital role in the development of new therapeutic options. They are carefully regulated, monitored and conducted in specific populations to assess safety and efficacy.
Currently, access to AVROBIO’s investigational therapies is possible through participation in clinical trials. Completing the necessary clinical trials and obtaining the data needed for review and approval by regulatory agencies is the fastest way toward making AVROBIO’s gene therapies potentially available to the greatest number of individuals in the future.
Find information on currently enrolling clinical trials for AVROBIO’s investigational gene therapies on clinicaltrials.gov.
- Whether based on available safety and efficacy data, sufficient evidence is established that the potential benefits to the patient(s) outweighs the potential risks.
- Whether there is adequate supply of the investigational gene therapy to complete the ongoing and planned clinical trials.
- Whether it will compromise or delay ongoing clinical trials or future access for the broader community.
If you have additional questions, please speak with your physician or contact firstname.lastname@example.org. We will acknowledge receipt and respond to your inquiry within seven days.
As more information and clinical data become available, AVROBIO may revise this policy. If you would like to receive regular updates about AVROBIO please email email@example.com.
Connect with our patient advocacy and engagement team.
Read about our mission and vision.
Learn more about our pipeline of investigational gene therapies.